Identification

Name
Drospirenone
Accession Number
DB01395
Type
Small Molecule
Groups
Approved
Description

Drospirenone is a synthetic progestin that is an analog to spironolactone. It is found in a number of birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. It was shown in animal studies that drospirenone exhibits antiandrogenic activity judging from accessory sex gland growth in castrated, androgen-treated, juvenile rats.

Structure
Thumb
Synonyms
  • 1,2-Dihydrospirorenone
  • 6beta,7Beta;15beta,16beta-dimethylene-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
  • 6β,7β,15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17 carbolactone
  • Dehydrospirorenone
  • Drospirenona
  • Drospirenonum
  • DRSP
External IDs
ZK-30595
Product Images
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AngeliqDrospirenone (.25 mg/1) + Estradiol (.5 mg/1)Tablet, film coatedOralBayer2012-02-29Not applicableUs
AngeliqDrospirenone (.5 mg/1) + Estradiol (1 mg/1)Tablet, film coatedOralPhysicians Total Care, Inc.2010-09-29Not applicableUs
AngeliqDrospirenone (.5 mg/1) + Estradiol (1 mg/1)Tablet, film coatedOralBayer2005-11-28Not applicableUs
AngeliqDrospirenone (1.0 mg) + Estradiol (1.0 mg)TabletOralBayer2008-10-20Not applicableCanada
BeyazDrospirenone (3 mg/1) + Ethinyl Estradiol (0.02 mg/1) + Levomefolate calcium (0.451 mg/1) + Levomefolate calcium (0.451 mg/1)KitBayer2010-10-07Not applicableUs50419 40720180113 27003 xgvnkl
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitNivagen Pharmaceuticals, Inc.2017-08-16Not applicableUs
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitA S Medication Solutions2015-08-172017-06-20Us
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitOralPharmaceutics International, Inc. (Pii)2017-10-26Not applicableUs
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitLupin Pharmaceuticals2012-12-31Not applicableUs
Drospirenone and Ethinyl EstradiolDrospirenone + Ethinyl EstradiolKitMylan Pharmaceuticals2015-08-28Not applicableUs
Categories
UNII
N295J34A25
CAS number
67392-87-4
Weight
Average: 366.4932
Monoisotopic: 366.219494826
Chemical Formula
C24H30O3
InChI Key
METQSPRSQINEEU-HXCATZOESA-N
InChI
InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
IUPAC Name
(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁹.0¹⁶,¹⁸]nonadecane-15,2'-oxolan]-5-ene-5',7-dione
SMILES
[H][C@@]12C[C@]1([H])[C@@]1([H])[C@]3([H])[C@]4([H])C[C@]4([H])[C@@]4(CCC(=O)O4)[C@@]3(C)CC[C@]1([H])[C@@]1(C)CCC(=O)C=C21

Pharmacology

Indication

For the prevention of pregnancy in women who elect an oral contraceptive.

Associated Conditions
Associated Therapies
Pharmacodynamics

Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic.

Mechanism of action

Progestins such as drospirenone diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

TargetActionsOrganism
AProgesterone receptor
agonist
Human
AMineralocorticoid receptor
antagonist
Human
AAndrogen receptor
antagonist
Human
Absorption

Oral bioavailability is approximately 76%.

Volume of distribution
Not Available
Protein binding

95-97%

Metabolism

Extensively metabolized following oral or intravenous administration. The two major metabolites are inactive and are formed independent of the CYP450 enzyme system. The metabolites are the acid form of drospirenone formed by opening of the lactone ring and the 4,5-dihydro-drospirenone-3-sulfate.

Route of elimination
Not Available
Half life

30 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Drospirenone.Experimental
(4R)-limonene(4R)-limonene may increase the hyperkalemic activities of Drospirenone.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Drospirenone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Drospirenone.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Drospirenone.Investigational
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Drospirenone.Experimental, Illicit
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Drospirenone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Drospirenone.Approved, Investigational
AceclofenacAceclofenac may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
AcemetacinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolDrospirenone may decrease the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Drospirenone.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Drospirenone.Approved, Vet Approved
AcitretinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Acitretin.Approved
AdapaleneAdapalene may increase the hyperkalemic activities of Drospirenone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Drospirenone.Experimental, Investigational
AlaproclateAlaproclate may increase the antiplatelet activities of Drospirenone.Experimental
AlclofenacAlclofenac may increase the hyperkalemic activities of Drospirenone.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Drospirenone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Drospirenone.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Drospirenone.Approved, Illicit
AliskirenDrospirenone may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AlitretinoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Alitretinoin.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Drospirenone.Investigational
AlminoprofenAlminoprofen may increase the hyperkalemic activities of Drospirenone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Drospirenone.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Drospirenone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Drospirenone.Illicit
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Drospirenone.Approved
AmilorideDrospirenone may increase the hyperkalemic activities of Amiloride.Approved
AmiodaroneThe metabolism of Drospirenone can be decreased when combined with Amiodarone.Approved, Investigational
AmobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Amobarbital.Approved, Illicit
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Drospirenone.Approved, Investigational
AndrographolideAndrographolide may increase the hyperkalemic activities of Drospirenone.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Drospirenone.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Drospirenone.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Drospirenone.Investigational
AnisodamineAnisodamine may increase the hyperkalemic activities of Drospirenone.Investigational
AntipyrineAntipyrine may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Drospirenone.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Drospirenone.Approved
ApocyninApocynin may increase the hyperkalemic activities of Drospirenone.Investigational
ApremilastApremilast may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
AprepitantThe serum concentration of Drospirenone can be decreased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Drospirenone.Approved, Investigational, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Drospirenone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Drospirenone.Approved, Investigational
ArtemetherThe serum concentration of Drospirenone can be decreased when it is combined with Artemether.Approved
AsunaprevirThe serum concentration of Drospirenone can be decreased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Drospirenone.Investigational
AtazanavirThe serum concentration of Drospirenone can be increased when it is combined with Atazanavir.Approved, Investigational
AzapropazoneAzapropazone may increase the hyperkalemic activities of Drospirenone.Withdrawn
AzelastineAzelastine may increase the hyperkalemic activities of Drospirenone.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Drospirenone.Investigational
BalsalazideBalsalazide may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
BarbexacloneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Barbital.Illicit
BazedoxifeneDrospirenone may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Drospirenone.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Drospirenone.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Drospirenone.Investigational
BenazeprilBenazepril may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
BendazacBendazac may increase the hyperkalemic activities of Drospirenone.Experimental
BenorilateBenorilate may increase the hyperkalemic activities of Drospirenone.Experimental
BenoxaprofenBenoxaprofen may increase the hyperkalemic activities of Drospirenone.Withdrawn
BenzydamineBenzydamine may increase the hyperkalemic activities of Drospirenone.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Drospirenone.Approved, Vet Approved
BevoniumBevonium may increase the hyperkalemic activities of Drospirenone.Experimental
BexaroteneThe serum concentration of Drospirenone can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Drospirenone.Experimental, Illicit, Withdrawn
BisacodylThe risk or severity of adverse effects can be increased when Drospirenone is combined with Bisacodyl.Approved
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Drospirenone.Approved, Investigational
BoceprevirThe serum concentration of Drospirenone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Drospirenone can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacBromfenac may increase the hyperkalemic activities of Drospirenone.Approved
BucillamineBucillamine may increase the hyperkalemic activities of Drospirenone.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Drospirenone.Approved
BufexamacBufexamac may increase the hyperkalemic activities of Drospirenone.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Drospirenone.Investigational, Withdrawn
BumadizoneBumadizone may increase the hyperkalemic activities of Drospirenone.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Drospirenone.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Drospirenone.Approved, Illicit, Vet Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.Approved
CandesartanCandesartan may increase the hyperkalemic activities of Drospirenone.Experimental
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Drospirenone.Approved
CandoxatrilCandoxatril may increase the hyperkalemic activities of Drospirenone.Experimental
CaptoprilCaptopril may increase the hyperkalemic activities of Drospirenone.Approved
CarbamazepineThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hyperkalemic activities of Drospirenone.Experimental, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Drospirenone.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Drospirenone.Illicit, Investigational, Vet Approved
CarprofenCarprofen may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the hyperkalemic activities of Drospirenone.Experimental
CelecoxibCelecoxib may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
CeritinibThe serum concentration of Drospirenone can be increased when it is combined with Ceritinib.Approved
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Drospirenone.Approved, Investigational
ChloroquineChloroquine may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Vet Approved
ChlorotrianiseneDrospirenone may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Drospirenone.Approved, Investigational
CholestyramineThe serum concentration of Drospirenone can be decreased when it is combined with Cholestyramine.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the hyperkalemic activities of Drospirenone.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Drospirenone.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Drospirenone.Experimental
CilazaprilCilazapril may increase the hyperkalemic activities of Drospirenone.Approved
CitalopramCitalopram may increase the antiplatelet activities of Drospirenone.Approved
ClarithromycinThe serum concentration of Drospirenone can be increased when it is combined with Clarithromycin.Approved
ClobazamThe serum concentration of Drospirenone can be decreased when it is combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Drospirenone.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Drospirenone.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Drospirenone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Drospirenone.Approved
ClonixinClonixin may increase the hyperkalemic activities of Drospirenone.Approved
ClorindioneDrospirenone may decrease the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe serum concentration of Drospirenone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Drospirenone can be increased when it is combined with Cobicistat.Approved
CodeineThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Codeine.Approved, Illicit
ColesevelamThe serum concentration of Drospirenone can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Drospirenone can be decreased when it is combined with Colestipol.Approved
Conestat alfaDrospirenone may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
Conjugated estrogensDrospirenone may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Drospirenone.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Drospirenone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Drospirenone.Approved, Investigational
CurcuminCurcumin may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
CyclosporineThe metabolism of Drospirenone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Drospirenone.Approved
DabrafenibThe serum concentration of Drospirenone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinDrospirenone may increase the thrombogenic activities of Daidzein.Experimental
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Drospirenone.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Drospirenone.Approved, Withdrawn
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Drospirenone.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Drospirenone.Investigational
DarexabanThe therapeutic efficacy of Darexaban can be decreased when used in combination with Drospirenone.Investigational
DarunavirThe serum concentration of Drospirenone can be decreased when it is combined with Darunavir.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Drospirenone.Approved, Investigational
DelaprilDelapril may increase the hyperkalemic activities of Drospirenone.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Drospirenone.Investigational
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Drospirenone.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Drospirenone.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Drospirenone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Drospirenone.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Drospirenone.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Drospirenone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Drospirenone.Vet Approved
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Drospirenone.Approved, Investigational, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Drospirenone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Drospirenone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Drospirenone.Approved, Investigational
DiclofenacThe risk or severity of hyperkalemia can be increased when Diclofenac is combined with Drospirenone.Approved, Vet Approved
DicoumarolDrospirenone may decrease the anticoagulant activities of Dicoumarol.Approved
DienestrolDrospirenone may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolDrospirenone may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideDifenpiramide may increase the hyperkalemic activities of Drospirenone.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Drospirenone.Approved
DiflunisalDiflunisal may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Drospirenone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Drospirenone.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Drospirenone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Drospirenone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Drospirenone.Experimental, Illicit
DiltiazemThe serum concentration of Drospirenone can be increased when it is combined with Diltiazem.Approved, Investigational
DiphenadioneDrospirenone may decrease the anticoagulant activities of Diphenadione.Experimental
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Drospirenone.Approved, Illicit
DocusateThe risk or severity of adverse effects can be increased when Drospirenone is combined with Docusate.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Drospirenone.Experimental
DroxicamDroxicam may increase the hyperkalemic activities of Drospirenone.Withdrawn
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Drospirenone.Approved, Investigational
DuloxetineDuloxetine may increase the antiplatelet activities of Drospirenone.Approved
DuvelisibDuvelisib may increase the hyperkalemic activities of Drospirenone.Investigational
E-6201E-6201 may increase the hyperkalemic activities of Drospirenone.Investigational
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Drospirenone.Approved, Vet Approved
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Drospirenone.Approved
EfavirenzThe serum concentration of Drospirenone can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Drospirenone.Approved
EnalaprilEnalapril may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hyperkalemic activities of Drospirenone.Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Drospirenone.Experimental
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Drospirenone.Approved
EpimestrolDrospirenone may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleEpirizole may increase the hyperkalemic activities of Drospirenone.Approved
EplerenoneDrospirenone may increase the hyperkalemic activities of Eplerenone.Approved
EprosartanEprosartan may increase the hyperkalemic activities of Drospirenone.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Drospirenone.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Drospirenone.Approved
EquolDrospirenone may increase the thrombogenic activities of Equol.Investigational
EscitalopramEscitalopram may increase the antiplatelet activities of Drospirenone.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Drospirenone can be decreased when it is combined with Eslicarbazepine acetate.Approved
Estradiol acetateDrospirenone may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateDrospirenone may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateDrospirenone may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolDrospirenone may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedDrospirenone may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneDrospirenone may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Drospirenone.Approved
EtanerceptEtanercept may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
EthenzamideEthenzamide may increase the hyperkalemic activities of Drospirenone.Experimental
Ethyl biscoumacetateDrospirenone may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Drospirenone.Approved, Illicit
EtodolacEtodolac may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Drospirenone.Withdrawn
EtoricoxibEtoricoxib may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Drospirenone.Illicit, Vet Approved
Evening primrose oilEvening primrose oil may increase the hyperkalemic activities of Drospirenone.Investigational, Nutraceutical
ExenatideThe serum concentration of Drospirenone can be decreased when it is combined with Exenatide.Approved, Investigational
ExisulindExisulind may increase the hyperkalemic activities of Drospirenone.Investigational
FelbamateThe serum concentration of Drospirenone can be decreased when it is combined with Felbamate.Approved
FelbinacFelbinac may increase the hyperkalemic activities of Drospirenone.Experimental
FenbufenFenbufen may increase the hyperkalemic activities of Drospirenone.Approved
FenoprofenFenoprofen may increase the hyperkalemic activities of Drospirenone.Approved
FentanylThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the hyperkalemic activities of Drospirenone.Experimental
FeprazoneFeprazone may increase the hyperkalemic activities of Drospirenone.Experimental
Ferulic acidFerulic acid may increase the hyperkalemic activities of Drospirenone.Experimental
FimasartanFimasartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Drospirenone.Approved, Investigational
FloctafenineFloctafenine may increase the hyperkalemic activities of Drospirenone.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Drospirenone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Drospirenone.Approved, Investigational
FluindioneDrospirenone may decrease the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Drospirenone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Drospirenone.Approved, Investigational
FlunixinFlunixin may increase the hyperkalemic activities of Drospirenone.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the hyperkalemic activities of Drospirenone.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Drospirenone.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Drospirenone.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Drospirenone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Drospirenone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Drospirenone.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Drospirenone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Drospirenone.Approved
FlurbiprofenFlurbiprofen may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Drospirenone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Drospirenone.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Drospirenone.Approved
FluvoxamineThe metabolism of Drospirenone can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Drospirenone.Approved, Investigational
ForasartanForasartan may increase the hyperkalemic activities of Drospirenone.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Drospirenone.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Drospirenone resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Drospirenone can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilFosinopril may increase the hyperkalemic activities of Drospirenone.Approved
FosphenytoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Fosphenytoin.Approved, Investigational
GabexateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Drospirenone.Investigational
GenisteinDrospirenone may increase the thrombogenic activities of Genistein.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Drospirenone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Drospirenone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Drospirenone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Drospirenone.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Drospirenone.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Drospirenone.Approved
GlycerinThe risk or severity of adverse effects can be increased when Drospirenone is combined with Glycerin.Approved, Investigational
GriseofulvinThe serum concentration of Drospirenone can be decreased when it is combined with Griseofulvin.Approved, Investigational, Vet Approved
GuacetisalGuacetisal may increase the hyperkalemic activities of Drospirenone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Drospirenone.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Drospirenone.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Drospirenone.Investigational
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Drospirenone.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Drospirenone.Approved, Illicit, Investigational
HexestrolDrospirenone may increase the thrombogenic activities of Hexestrol.Withdrawn
HexobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Hexobarbital.Approved
HigenamineHigenamine may increase the hyperkalemic activities of Drospirenone.Investigational
Human C1-esterase inhibitorDrospirenone may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Drospirenone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Drospirenone.Approved, Vet Approved
Hydrocortisone acetateThe serum concentration of Hydrocortisone acetate can be increased when it is combined with Drospirenone.Approved, Vet Approved
Hydrocortisone butyrateThe serum concentration of Hydrocortisone butyrate can be increased when it is combined with Drospirenone.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Drospirenone.Approved, Illicit
IbuprofenThe risk or severity of hyperkalemia can be increased when Ibuprofen is combined with Drospirenone.Approved
IbuproxamIbuproxam may increase the hyperkalemic activities of Drospirenone.Withdrawn
IcatibantIcatibant may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
IdelalisibThe serum concentration of Drospirenone can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Drospirenone.Investigational
ImidaprilImidapril may increase the hyperkalemic activities of Drospirenone.Investigational
Imidazole salicylateImidazole salicylate may increase the hyperkalemic activities of Drospirenone.Experimental
IndalpineIndalpine may increase the antiplatelet activities of Drospirenone.Investigational, Withdrawn
IndinavirThe serum concentration of Drospirenone can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may increase the hyperkalemic activities of Drospirenone.Investigational
IndomethacinIndomethacin may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
IndoprofenIndoprofen may increase the hyperkalemic activities of Drospirenone.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Drospirenone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Drospirenone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Drospirenone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Drospirenone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Drospirenone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Drospirenone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Drospirenone.Approved
IrbesartanIrbesartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
IsotretinoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Isotretinoin.Approved
IsoxicamIsoxicam may increase the hyperkalemic activities of Drospirenone.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Drospirenone.Investigational
ItraconazoleThe serum concentration of Drospirenone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneKebuzone may increase the hyperkalemic activities of Drospirenone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Drospirenone.Approved, Investigational
KetoconazoleThe serum concentration of Drospirenone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
KetorolacThe risk or severity of hyperkalemia can be increased when Ketorolac is combined with Drospirenone.Approved
LactuloseThe risk or severity of adverse effects can be increased when Drospirenone is combined with Lactulose.Approved
LamotrigineDrospirenone may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.Approved, Investigational
LeflunomideLeflunomide may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Drospirenone.Approved
LetaxabanThe therapeutic efficacy of Letaxaban can be decreased when used in combination with Drospirenone.Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Drospirenone.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Drospirenone.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Drospirenone.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Drospirenone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Drospirenone.Approved
LisinoprilLisinopril may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
LisofyllineLisofylline may increase the hyperkalemic activities of Drospirenone.Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Drospirenone.Illicit
LonazolacLonazolac may increase the hyperkalemic activities of Drospirenone.Experimental
LopinavirThe serum concentration of Drospirenone can be decreased when it is combined with Lopinavir.Approved
LornoxicamLornoxicam may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
LosartanThe risk or severity of hyperkalemia can be increased when Losartan is combined with Drospirenone.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Drospirenone.Approved
LoxoprofenLoxoprofen may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
LumacaftorThe serum concentration of Drospirenone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the hyperkalemic activities of Drospirenone.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Drospirenone is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MasoprocolMasoprocol may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Drospirenone.Investigational
Meclofenamic acidMeclofenamic acid may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Drospirenone.Approved
Mefenamic acidMefenamic acid may increase the hyperkalemic activities of Drospirenone.Approved
MelagatranThe therapeutic efficacy of Melagatran can be decreased when used in combination with Drospirenone.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Drospirenone.Vet Approved
MeloxicamMeloxicam may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Drospirenone.Experimental
MesalazineMesalazine may increase the hyperkalemic activities of Drospirenone.Approved
MestranolDrospirenone may increase the thrombogenic activities of Mestranol.Approved
MetamizoleMetamizole may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Drospirenone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Drospirenone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Drospirenone.Approved, Illicit
MethallenestrilDrospirenone may increase the thrombogenic activities of Methallenestril.Experimental
MethohexitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Drospirenone.Approved, Vet Approved
MetreleptinThe serum concentration of Drospirenone can be decreased when it is combined with Metreleptin.Approved
MibefradilThe serum concentration of Drospirenone can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Drospirenone can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Drospirenone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Drospirenone.Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Drospirenone.Approved, Investigational
Mineral oilThe risk or severity of adverse effects can be increased when Drospirenone is combined with Mineral oil.Approved, Vet Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Drospirenone.Approved, Investigational
MizoribineMizoribine may increase the hyperkalemic activities of Drospirenone.Investigational
MoexiprilMoexipril may increase the hyperkalemic activities of Drospirenone.Approved
MofebutazoneMofebutazone may increase the hyperkalemic activities of Drospirenone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Drospirenone.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Drospirenone.Approved, Investigational
MoxestrolDrospirenone may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
Mycophenolic acidThe serum concentration of Drospirenone can be decreased when it is combined with Mycophenolic acid.Approved
NabumetoneNabumetone may increase the hyperkalemic activities of Drospirenone.Approved
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Drospirenone.Approved, Investigational
NafamostatNafamostat may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
NaftifineNaftifine may increase the hyperkalemic activities of Drospirenone.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Drospirenone.Approved
NaproxenThe risk or severity of hyperkalemia can be increased when Naproxen is combined with Drospirenone.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Drospirenone.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Drospirenone.Investigational
NefazodoneThe serum concentration of Drospirenone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Drospirenone can be decreased when it is combined with Nelfinavir.Approved
NepafenacNepafenac may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
NevirapineThe serum concentration of Drospirenone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Drospirenone can be decreased when combined with Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Drospirenone.Experimental
NifenazoneNifenazone may increase the hyperkalemic activities of Drospirenone.Experimental
Niflumic AcidNiflumic Acid may increase the hyperkalemic activities of Drospirenone.Approved
NimesulideThe risk or severity of hyperkalemia can be increased when Nimesulide is combined with Drospirenone.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Drospirenone.Approved, Investigational
NitroaspirinNitroaspirin may increase the hyperkalemic activities of Drospirenone.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Drospirenone.Approved, Illicit
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Drospirenone.Investigational
OlmesartanOlmesartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
OlopatadineOlopatadine may increase the hyperkalemic activities of Drospirenone.Approved
OlsalazineOlsalazine may increase the hyperkalemic activities of Drospirenone.Approved
OmapatrilatOmapatrilat may increase the hyperkalemic activities of Drospirenone.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Drospirenone.Approved, Illicit
OrgoteinOrgotein may increase the hyperkalemic activities of Drospirenone.Vet Approved
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Drospirenone.Investigational
OxaprozinOxaprozin may increase the hyperkalemic activities of Drospirenone.Approved
OxcarbazepineThe serum concentration of Drospirenone can be decreased when it is combined with Oxcarbazepine.Approved
OxycodoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may increase the hyperkalemic activities of Drospirenone.Approved, Withdrawn
PalmidrolPalmidrol may increase the hyperkalemic activities of Drospirenone.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Drospirenone.Approved
ParecoxibParecoxib may increase the hyperkalemic activities of Drospirenone.Approved
ParthenolideParthenolide may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
Pentaerythritol TetranitrateThe therapeutic efficacy of Pentaerythritol Tetranitrate can be decreased when used in combination with Drospirenone.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Drospirenone.Approved, Vet Approved
PentobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Drospirenone.Approved
PerampanelThe serum concentration of Drospirenone can be decreased when it is combined with Perampanel.Approved
PerindoprilPerindopril may increase the hyperkalemic activities of Drospirenone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Drospirenone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Drospirenone.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Drospirenone.Approved, Investigational, Withdrawn
PhenindioneDrospirenone may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Drospirenone.Experimental
PhenprocoumonDrospirenone may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the hyperkalemic activities of Drospirenone.Approved, Vet Approved
PhenytoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Drospirenone.Approved, Investigational
PirfenidonePirfenidone may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Drospirenone.Approved, Investigational
PiroxicamPiroxicam may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
PirprofenPirprofen may increase the hyperkalemic activities of Drospirenone.Experimental
Polyestradiol phosphateDrospirenone may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PosaconazoleThe serum concentration of Drospirenone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium bicarbonateThe risk or severity of hyperkalemia can be increased when Potassium bicarbonate is combined with Drospirenone.Approved
Potassium cationThe risk or severity of hyperkalemia can be increased when Potassium is combined with Drospirenone.Approved, Investigational
Potassium CitrateThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Drospirenone.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Drospirenone.Approved, Investigational
PranoprofenPranoprofen may increase the hyperkalemic activities of Drospirenone.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Drospirenone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Drospirenone.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Drospirenone.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Drospirenone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Drospirenone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Drospirenone.Approved, Experimental, Investigational
PrimidoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Primidone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the hyperkalemic activities of Drospirenone.Experimental
PromestrieneDrospirenone may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolPropacetamol may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
PropyphenazonePropyphenazone may increase the hyperkalemic activities of Drospirenone.Experimental
ProquazoneProquazone may increase the hyperkalemic activities of Drospirenone.Experimental
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Drospirenone.Approved
Protein S humanThe therapeutic efficacy of Protein S human can be decreased when used in combination with Drospirenone.Approved
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Drospirenone.Approved
PrucaloprideThe serum concentration of Drospirenone can be decreased when it is combined with Prucalopride.Approved
PTC299PTC299 may increase the hyperkalemic activities of Drospirenone.Investigational
QuinaprilQuinapril may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
QuinestrolDrospirenone may increase the thrombogenic activities of Quinestrol.Approved
RamiprilRamipril may increase the hyperkalemic activities of Drospirenone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Drospirenone.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Drospirenone.Approved, Investigational
RescinnamineRescinnamine may increase the hyperkalemic activities of Drospirenone.Approved
ResveratrolResveratrol may increase the hyperkalemic activities of Drospirenone.Approved, Experimental, Investigational
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Drospirenone.Approved, Investigational
RifabutinThe serum concentration of Drospirenone can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Drospirenone can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Drospirenone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Drospirenone can be decreased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Drospirenone.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Drospirenone.Approved
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Drospirenone.Approved
RofecoxibRofecoxib may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Drospirenone.Approved, Investigational
SacubitrilSacubitril may increase the hyperkalemic activities of Drospirenone.Approved
SalicylamideSalicylamide may increase the hyperkalemic activities of Drospirenone.Approved
Salicylic acidThe risk or severity of hyperkalemia can be increased when Salicylic acid is combined with Drospirenone.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the hyperkalemic activities of Drospirenone.Approved
SaprisartanSaprisartan may increase the hyperkalemic activities of Drospirenone.Experimental
SaquinavirThe serum concentration of Drospirenone can be decreased when it is combined with Saquinavir.Approved, Investigational
SaralasinSaralasin may increase the hyperkalemic activities of Drospirenone.Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Drospirenone.Approved
SecobarbitalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SecoisolariciresinolDrospirenone may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Drospirenone.Approved, Investigational, Vet Approved
SemapimodSemapimod may increase the hyperkalemic activities of Drospirenone.Investigational
SeratrodastSeratrodast may increase the hyperkalemic activities of Drospirenone.Approved
SerrapeptaseSerrapeptase may increase the hyperkalemic activities of Drospirenone.Investigational
SertralineSertraline may increase the antiplatelet activities of Drospirenone.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Drospirenone.Approved, Investigational
Sodium CitrateDrospirenone may decrease the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicDrospirenone may increase the nephrotoxic activities of Sodium phosphate, monobasic.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Drospirenone.Investigational
SpiraprilSpirapril may increase the hyperkalemic activities of Drospirenone.Approved
SpironolactoneDrospirenone may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the hyperkalemic activities of Drospirenone.Investigational
St. John's WortThe therapeutic efficacy of Drospirenone can be decreased when used in combination with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Drospirenone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Drospirenone.Approved, Investigational
SugammadexThe serum concentration of Drospirenone can be decreased when it is combined with Sugammadex.Approved
SulfasalazineThe risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Drospirenone.Approved
SulindacThe risk or severity of hyperkalemia can be increased when Sulindac is combined with Drospirenone.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Drospirenone.Approved, Investigational
SuprofenSuprofen may increase the hyperkalemic activities of Drospirenone.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the hyperkalemic activities of Drospirenone.Experimental
Synthetic Conjugated Estrogens, ADrospirenone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BDrospirenone may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Drospirenone.Approved
TarenflurbilTarenflurbil may increase the hyperkalemic activities of Drospirenone.Investigational
TasosartanTasosartan may increase the hyperkalemic activities of Drospirenone.Approved
TelaprevirThe serum concentration of Drospirenone can be decreased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Drospirenone can be increased when it is combined with Telithromycin.Approved
TelmisartanTelmisartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
TemocaprilTemocapril may increase the hyperkalemic activities of Drospirenone.Experimental, Investigational
TenidapTenidap may increase the hyperkalemic activities of Drospirenone.Experimental
TenoxicamTenoxicam may increase the hyperkalemic activities of Drospirenone.Approved
TepoxalinTepoxalin may increase the hyperkalemic activities of Drospirenone.Vet Approved
TeriflunomideTeriflunomide may increase the hyperkalemic activities of Drospirenone.Approved
ThalidomideDrospirenone may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Thiopental.Approved, Vet Approved
Tiaprofenic acidTiaprofenic acid may increase the hyperkalemic activities of Drospirenone.Approved
TiboloneDrospirenone may increase the thrombogenic activities of Tibolone.Approved, Investigational
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Drospirenone.Experimental
TinoridineTinoridine may increase the hyperkalemic activities of Drospirenone.Investigational
TioclomarolDrospirenone may decrease the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Drospirenone can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Drospirenone.Approved, Withdrawn
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Drospirenone.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Drospirenone.Approved, Investigational
Tolfenamic AcidThe risk or severity of hyperkalemia can be increased when Tolfenamic Acid is combined with Drospirenone.Approved, Investigational
TolmetinTolmetin may increase the hyperkalemic activities of Drospirenone.Approved
TopiramateThe serum concentration of Drospirenone can be decreased when it is combined with Topiramate.Approved
TramadolThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Tramadol.Approved, Investigational
TrandolaprilTrandolapril may increase the hyperkalemic activities of Drospirenone.Approved
Tranexamic AcidTranexamic Acid may increase the thrombogenic activities of Drospirenone.Approved
TretinoinThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Drospirenone.Approved, Vet Approved
TriamtereneDrospirenone may increase the hyperkalemic activities of Triamterene.Approved
TribenosideTribenoside may increase the hyperkalemic activities of Drospirenone.Experimental
TriptolideTriptolide may increase the hyperkalemic activities of Drospirenone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Drospirenone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of hyperkalemia can be increased when Trolamine salicylate is combined with Drospirenone.Approved
TroxerutinThe therapeutic efficacy of Troxerutin can be decreased when used in combination with Drospirenone.Investigational
UlipristalThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Ulipristal.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Drospirenone.Approved
ValdecoxibValdecoxib may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
VerapamilThe metabolism of Drospirenone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Drospirenone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Drospirenone.Approved, Investigational
VoriconazoleThe serum concentration of Drospirenone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinDrospirenone may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Drospirenone.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the hyperkalemic activities of Drospirenone.Approved, Investigational
ZeranolDrospirenone may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonZileuton may increase the hyperkalemic activities of Drospirenone.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Drospirenone.Withdrawn
ZofenoprilZofenopril may increase the hyperkalemic activities of Drospirenone.Experimental
ZomepiracZomepirac may increase the hyperkalemic activities of Drospirenone.Withdrawn
Food Interactions
  • Food reduces the rate of absorption, but not the extent of absorption.

References

Synthesis Reference

DOI: 10.1002/cjoc.201201147

General References
  1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [PubMed:11024226]
  2. Wichianpitaya J, Taneepanichskul S: A comparative efficacy of low-dose combined oral contraceptives containing desogestrel and drospirenone in premenstrual symptoms. Obstet Gynecol Int. 2013;2013:487143. doi: 10.1155/2013/487143. Epub 2013 Feb 20. [PubMed:23577032]
External Links
Human Metabolome Database
HMDB0015467
KEGG Drug
D03917
PubChem Compound
68873
PubChem Substance
46507653
ChemSpider
62105
ChEBI
50838
ChEMBL
CHEMBL1509
Therapeutic Targets Database
DAP001206
PharmGKB
PA164749409
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Drospirenone
ATC Codes
G03FA17 — Drospirenone and estrogenG03AC10 — DrospirenoneG03AA12 — Drospirenone and ethinylestradiol
FDA label
Download (292 KB)
MSDS
Download (567 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingSupportive CareEndometriosis of Uterus1
1CompletedNot AvailableHealthy Volunteers2
1CompletedOtherContraception1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentContraception2
1RecruitingOtherHealthy Volunteers1
1RecruitingPreventionContraception1
1TerminatedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusTreatmentPolycystic Ovaries Syndrome1
1, 2CompletedPreventionContraception / Hemostasis Parameter / Liver Metabolism1
2CompletedPreventionContraception1
2CompletedPreventionPrevention of Pregnancy1
2CompletedTreatmentHigh Blood Pressure (Hypertension) / One to five years postmenopausal / Pre-Hypertension1
2CompletedTreatmentOral Contraceptives (OC)1
2TerminatedTreatmentDepression / PMDD / Premenstrual Dysphoric Disorder / Premenstrual Syndrome1
2TerminatedTreatmentHidradenitis Suppurativa (HS)1
3Active Not RecruitingPreventionContraception1
3Active Not RecruitingTreatmentContraception2
3CompletedPreventionContraception9
3CompletedPreventionContraception / Neural Tube Defects (NTDs) / Oral Contraceptives (OC)1
3CompletedPreventionContraception / Oral Contraceptives (OC) / Ovulation Inhibition1
3CompletedTreatmentAcne Vulgaris4
3CompletedTreatmentDysmenorrhea1
3CompletedTreatmentEndometriosis1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHigh Blood Pressure (Hypertension) / One to five years postmenopausal1
3CompletedTreatmentOral Contraceptives (OC)1
3CompletedTreatmentPolycystic Ovaries Syndrome2
3CompletedTreatmentPremenstrual Dysphoric Disorder ( PMDD)1
3CompletedTreatmentPremenstrual Syndrome1
3CompletedTreatmentPrimary Dysmenorrhoea1
3CompletedTreatmentVasomotor Symptoms2
3Unknown StatusNot AvailableContraceptive Affecting Blood Pressure / Contraceptive Affecting the Autonomic Nervous System1
3WithdrawnNot AvailableMetrorrhagia1
3WithdrawnTreatmentContraception1
3WithdrawnTreatmentDysmenorrhea1
4CompletedNot AvailableBlood Pressures / Contraception1
4CompletedNot AvailableContraception2
4CompletedBasic ScienceAdverse Effect of Oral Contraceptives, Subsequent Encounter1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedTreatmentContraception1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentPolycystic Ovaries Syndrome2
4CompletedTreatmentPremenstrual Dysphoric Disorder1
4CompletedTreatmentPremenstrual Syndrome1
4CompletedTreatmentPrimary Dysmenorrhoea1
4CompletedTreatmentOne to five years postmenopausal1
4Enrolling by InvitationTreatmentBody Weight Changes1
4Unknown StatusNot AvailableDysmenorrhea / Endometriotic Cysts / Painful Intercourse / Pelvic Pain1
4Unknown StatusPreventionHyperandrogenism / Menstrual Irregularities / Polycystic Ovarian Syndrome1
4Unknown StatusTreatmentContraceptive Methods Comparison1
Not AvailableActive Not RecruitingNot AvailableDysmenorrhea1
Not AvailableCompletedNot AvailableAcne / Contraception / Premenstrual Syndrome1
Not AvailableCompletedNot AvailableContraception4
Not AvailableCompletedNot AvailableMetabolic Syndromes / Polycystic Ovaries Syndrome1
Not AvailableCompletedNot AvailablePostmenopausal Osteoporosis (PMO) / Postmenopausal Period1
Not AvailableCompletedTreatmentDepression / Premenstrual Syndrome1
Not AvailableCompletedTreatmentEstro-progestin Drugs / Polycystic Ovaries Syndrome1
Not AvailableCompletedTreatmentOne to five years postmenopausal1
Not AvailableNot Yet RecruitingTreatmentPremature Menopause / Primary Ovarian Insufficiency1
Not AvailableRecruitingNot AvailableInfertilities1
Not AvailableUnknown StatusTreatmentEndothelial Dysfunction / Polycystic Ovaries Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
Kit
TabletOral
KitOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6787531No2000-08-312020-08-31Us
US6933395No1997-08-112017-08-11Us
US8906890No2011-10-222031-10-22Us
US6987101No1997-12-222017-12-22Us
US7163931No2001-12-202021-12-20Us
US6958326No2001-12-202021-12-20Us
US5798338No1995-07-102015-07-10Us
US6441168No2002-07-302022-07-30Us
US8617597No2010-02-082030-02-08Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00225 mg/mLALOGPS
logP2.36ALOGPS
logP3.37ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)-5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.37 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity101.68 m3·mol-1ChemAxon
Polarizability41.81 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9383
Caco-2 permeable+0.6376
P-glycoprotein substrateSubstrate0.6524
P-glycoprotein inhibitor IInhibitor0.6171
P-glycoprotein inhibitor IINon-inhibitor0.6726
Renal organic cation transporterNon-inhibitor0.7005
CYP450 2C9 substrateNon-substrate0.796
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6964
CYP450 1A2 substrateNon-inhibitor0.5534
CYP450 2C9 inhibitorNon-inhibitor0.8665
CYP450 2D6 inhibitorNon-inhibitor0.9336
CYP450 2C19 inhibitorNon-inhibitor0.7754
CYP450 3A4 inhibitorNon-inhibitor0.8355
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8541
Ames testNon AMES toxic0.9163
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.9757
Rat acute toxicity1.9430 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9393
hERG inhibition (predictor II)Non-inhibitor0.8215
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (37.1 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as spironolactones and derivatives. These are steroid lactones with a structure based on the spironolactone skeleton.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid lactones
Direct Parent
Spironolactones and derivatives
Alternative Parents
Cyclohexenones / Gamma butyrolactones / Tetrahydrofurans / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Spironolactone / Cyclohexenone / Gamma butyrolactone / Tetrahydrofuran / Cyclic ketone / Lactone / Ketone / Carboxylic acid ester / Oxacycle / Organoheterocyclic compound
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
3-oxo steroid, 3-oxo Delta(4)-steroid, steroid lactone (CHEBI:50838)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [PubMed:11024226]
  2. Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR: Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41. Epub 2005 Sep 12. [PubMed:16157482]
  3. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH: The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996 Oct;54(4):243-51. [PubMed:8922878]
  4. Arias-Loza PA, Hu K, Schafer A, Bauersachs J, Quaschning T, Galle J, Jazbutyte V, Neyses L, Ertl G, Fritzemeier KH, Hegele-Hartung C, Pelzer T: Medroxyprogesterone acetate but not drospirenone ablates the protective function of 17 beta-estradiol in aldosterone salt-treated rats. Hypertension. 2006 Nov;48(5):994-1001. Epub 2006 Sep 25. [PubMed:17000933]
  5. Sitruk-Ware R: New progestagens for contraceptive use. Hum Reprod Update. 2006 Mar-Apr;12(2):169-78. Epub 2005 Nov 16. [PubMed:16291771]
  6. Sitruk-Ware R: New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Aging. 2004;21(13):865-83. [PubMed:15493951]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [PubMed:11024226]
  2. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH: The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996 Oct;54(4):243-51. [PubMed:8922878]
  3. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E: Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995 Jun 12;761:311-35. [PubMed:7625729]
  4. Oelkers WK: Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996 Apr;61(4):166-71. [PubMed:8732994]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [PubMed:11024226]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Maia H Jr, Casoy J, Athayde C, Valente Filho J, Coutinho EM: The effect of a continuous regimen of drospirenone 3 mg/ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium. Eur J Contracept Reprod Health Care. 2010 Feb;15(1):35-40. doi: 10.3109/13625180903383928. [PubMed:20063991]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Koitka M, Hochel J, Gieschen H, Borchert HH: Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity. J Pharm Biomed Anal. 2010 Feb 5;51(3):664-78. doi: 10.1016/j.jpba.2009.09.023. Epub 2009 Sep 23. [PubMed:19850433]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wiesinger H, Berse M, Klein S, Gschwend S, Hochel J, Zollmann FS, Schutt B: Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. Br J Clin Pharmacol. 2015 Dec;80(6):1399-410. doi: 10.1111/bcp.12745. Epub 2015 Oct 28. [PubMed:26271371]

Drug created on July 08, 2007 11:03 / Updated on August 02, 2018 04:35